glycosylated and unglycosylated TPO receptor/c-Mpl
Immunogène
KLH-conjugated, synthetic peptide corresponding to amino acids 615-628 of human TPO (thrombopoietin) receptor (C-ANHSYLPLSYWQQP)
Application
Anti-TPOR/c-Mpl Antibody is an antibody against TPOR/c-Mpl for use in IP, WB, IH.
Research Category Signaling
Research Sub Category Growth Factors & Receptors
Qualité
routinely evaluated by immunoblot on RIPA lysates from DAMI cells
Description de la cible
68.5 kDa (calculated)
Forme physique
0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
Protein A chromatography
Stockage et stabilité
2 years at -20°C
Informations légales
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 1
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Journal of cellular and molecular medicine, 24(21), 12491-12503 (2020-09-22)
Thrombocyte formation from megakaryocyte and their progenitor cells is tightly regulated by thrombopoietin (TPO) and its receptor c-MPL, thereby maintaining physiological functionality and numbers of circulating platelets. In patients, dysfunction of this regulation could cause thrombocytopenia or myeloproliferative syndromes. Since
Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Sugita, M; Kalota, A; Gewirtz, AM; Carroll, M
Leukemia null
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
Erickson-Miller, CL; Pillarisetti, K; Kirchner, J; Figueroa, DJ; Ottesen, L; Martin et al.
To genetically and functionally characterize mutations of c-Mpl that lead to thrombocytopenia in a child with congenital amegakaryocytic thrombocytopenia. We identified two c-Mpl mutations in a child with clinical features of congenital amegakaryocytic thrombocytopenia, one a previously described mutation in
Recently, we demonstrated a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV) platelets and megakaryocytes using an antiserum against the Mpl extracellular domain. To further examine this abnormality, we raised an antibody to the
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
